Bridgefront Capital’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
JT
PA
NAMI
Bridgefront Capital's TVTX Position: Q2 2026 in Review
Bridgefront Capital opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 3,715 shares worth $211K. The stake represents 0.06% of the portfolio and ranks #442 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in TVTX as recently as Q1 2025.
Bridgefront Capital first reported a position in TVTX in Q4 2023 and has held it in 5 quarters since. The position peaked at $247K in Q3 2024. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.
- Bridgefront Capital held 3,715 shares of Travere Therapeutics worth $211K as of Q2 2026.
- Travere Therapeutics was a new Bridgefront Capital position in Q2 2026.
- Travere Therapeutics made up 0.06% of Bridgefront Capital's portfolio in Q2 2026, its #442 holding.
- Bridgefront Capital first reported a position in Travere Therapeutics in Q4 2023 and has held it in 5 quarters since.
- Bridgefront Capital's Travere Therapeutics position peaked at $247K in Q3 2024.
- 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.
Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.